Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 413

1.

Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota.

Morgillo F, Dallio M, Della Corte CM, Gravina AG, Viscardi G, Loguercio C, Ciardiello F, Federico A.

Neoplasia. 2018 May 30;20(7):721-733. doi: 10.1016/j.neo.2018.05.002. [Epub ahead of print] Review. No abstract available.

2.

Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program.

Cremolini C, Rossini D, Martinelli E, Pietrantonio F, Lonardi S, Noventa S, Tamburini E, Frassineti GL, Mosconi S, Nichetti F, Murgioni S, Troiani T, Borelli B, Zucchelli G, Dal Maso A, Sforza V, Masi G, Antoniotti C, Di Bartolomeo M, Miceli R, Ciardiello F, Falcone A.

Oncologist. 2018 May 8. pii: theoncologist.2017-0573. doi: 10.1634/theoncologist.2017-0573. [Epub ahead of print]

PMID:
29739893
3.

Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells.

Ciaramella V, Della Corte CM, Di Mauro C, Tomassi S, Di Maro S, Troiani T, Martinelli E, Bianco R, Cosconati S, Pierantoni R, Meccariello R, Chianese R, Ciardiello F, Morgillo F.

Oncotarget. 2018 Apr 10;9(27):19273-19282. doi: 10.18632/oncotarget.25018. eCollection 2018 Apr 10.

4.

Kisspeptin and Cancer: Molecular Interaction, Biological Functions, and Future Perspectives.

Ciaramella V, Della Corte CM, Ciardiello F, Morgillo F.

Front Endocrinol (Lausanne). 2018 Mar 27;9:115. doi: 10.3389/fendo.2018.00115. eCollection 2018. Review.

5.

Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells.

Graziani V, Scognamiglio M, Belli V, Esposito A, D'Abrosca B, Chambery A, Russo R, Panella M, Russo A, Ciardiello F, Troiani T, Potenza N, Fiorentino A.

Sci Rep. 2018 Mar 28;8(1):5309. doi: 10.1038/s41598-018-23704-9.

6.

Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models.

Della Corte CM, Ciaramella V, Cardone C, La Monica S, Alfieri R, Petronini PG, Malapelle U, Vigliar E, Pepe F, Troncone G, Castellone MD, Troiani T, Martinelli E, Ciardiello F, Morgillo F.

J Thorac Oncol. 2018 Jun;13(6):810-820. doi: 10.1016/j.jtho.2018.02.025. Epub 2018 Mar 8.

PMID:
29526823
7.

Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03).

Pinto C, Di Bisceglie M, Di Fabio F, Bochicchio A, Latiano T, Cordio S, Rosati G, Aschele C, Marino A, Bergamo F, Bustreo S, Frassineti L, Ciardiello F, Damato A, Giaquinta S, Baldari D, Boni L.

Oncologist. 2018 Mar 9. pii: theoncologist.2017-0484. doi: 10.1634/theoncologist.2017-0484. [Epub ahead of print]

PMID:
29523646
8.

Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge.

Ameri P, Canepa M, Anker MS, Belenkov Y, Bergler-Klein J, Cohen-Solal A, Farmakis D, López-Fernández T, Lainscak M, Pudil R, Ruschitska F, Seferovic P, Filippatos G, Coats A, Suter T, Von Haehling S, Ciardiello F, de Boer RA, Lyon AR, Tocchetti CG; Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology.

Eur J Heart Fail. 2018 May;20(5):879-887. doi: 10.1002/ejhf.1165. Epub 2018 Feb 21. Review.

PMID:
29464808
9.

Global cancer control: responding to the growing burden, rising costs and inequalities in access.

Prager GW, Braga S, Bystricky B, Qvortrup C, Criscitiello C, Esin E, Sonke GS, Martínez GA, Frenel JS, Karamouzis M, Strijbos M, Yazici O, Bossi P, Banerjee S, Troiani T, Eniu A, Ciardiello F, Tabernero J, Zielinski CC, Casali PG, Cardoso F, Douillard JY, Jezdic S, McGregor K, Bricalli G, Vyas M, Ilbawi A.

ESMO Open. 2018 Feb 2;3(2):e000285. doi: 10.1136/esmoopen-2017-000285. eCollection 2018.

10.

Role and targeting of anaplastic lymphoma kinase in cancer.

Della Corte CM, Viscardi G, Di Liello R, Fasano M, Martinelli E, Troiani T, Ciardiello F, Morgillo F.

Mol Cancer. 2018 Feb 19;17(1):30. doi: 10.1186/s12943-018-0776-2. Review.

11.

Computed tomography densitometric study of anti-angiogenic effect of regorafenib in colorectal cancer liver metastasis.

Reginelli A, Clemente A, Cardone C, Urraro F, Izzo A, Martinelli E, Troiani T, Ciardiello F, Brunese L, Cappabianca S.

Future Oncol. 2018 Feb 13. doi: 10.2217/fon-2017-0687. [Epub ahead of print]

PMID:
29433345
12.

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.

Montagut C, Argilés G, Ciardiello F, Poulsen TT, Dienstmann R, Kragh M, Kopetz S, Lindsted T, Ding C, Vidal J, Clausell-Tormos J, Siravegna G, Sánchez-Martín FJ, Koefoed K, Pedersen MW, Grandal MM, Dvorkin M, Wyrwicz L, Rovira A, Cubillo A, Salazar R, Desseigne F, Nadal C, Albanell J, Zagonel V, Siena S, Fumi G, Rospo G, Nadler P, Horak ID, Bardelli A, Tabernero J.

JAMA Oncol. 2018 Apr 12;4(4):e175245. doi: 10.1001/jamaoncol.2017.5245. Epub 2018 Apr 12.

13.

Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.

Gridelli C, Baas P, Barlesi F, Ciardiello F, Crinò L, Felip E, Gadgeel S, Papadimitrakopoulou V, Paz-Ares L, Planchard D, Perol M, Hanna N, Sgambato A, Casaluce F, de Marinis F.

Clin Lung Cancer. 2018 Jul;19(4):301-314. doi: 10.1016/j.cllc.2017.12.010. Epub 2017 Dec 22. Review.

PMID:
29396237
14.

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case.

Martinelli E, Troiani T, Sforza V, Martini G, Cardone C, Vitiello PP, Ciardiello D, Rachiglio AM, Normanno N, Sartore-Bianchi A, Marsoni S, Bardelli A, Siena S, Ciardiello F.

ESMO Open. 2018 Jan 10;3(1):e000299. doi: 10.1136/esmoopen-2017-000299. eCollection 2018.

15.

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.

Van Cutsem E, Mayer RJ, Laurent S, Winkler R, Grávalos C, Benavides M, Longo-Munoz F, Portales F, Ciardiello F, Siena S, Yamaguchi K, Muro K, Denda T, Tsuji Y, Makris L, Loehrer P, Lenz HJ, Ohtsu A; RECOURSE Study Group.

Eur J Cancer. 2018 Feb;90:63-72. doi: 10.1016/j.ejca.2017.10.009. Epub 2017 Dec 21.

16.

Novel In Vitro Cancer Models for Optimizing Anti-EGFR Therapies.

Napolitano S, Ciardiello F.

Clin Cancer Res. 2018 Feb 15;24(4):727-729. doi: 10.1158/1078-0432.CCR-17-2937. Epub 2017 Dec 8.

PMID:
29222163
17.

Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment.

Martinelli E, Sforza V, Cardone C, Capasso A, Nappi A, Martini G, Napolitano S, Rachiglio AM, Normanno N, Cappabianca S, Reginelli A, Bisceglie MD, Latiano TP, Maiello E, Orditura M, De Vita F, Morgillo F, Ciardiello F, Troiani T.

ESMO Open. 2017 Jul 29;2(3):e000177. doi: 10.1136/esmoopen-2017-000177. eCollection 2017.

18.

The Cancer Moonshot from a European perspective.

Ciardiello F, Tabernero J.

Lancet Oncol. 2017 Nov;18(11):e626. doi: 10.1016/S1470-2045(17)30798-2. Epub 2017 Oct 31. No abstract available.

PMID:
29208380
19.

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.

Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh KH, Grothey A, Zhang S, Ahn JB, Mastura MY, Chong D, Chen LT, Kopetz S, Eguchi-Nakajima T, Ebi H, Ohtsu A, Cervantes A, Muro K, Tabernero J, Minami H, Ciardiello F, Douillard JY.

Ann Oncol. 2018 Jan 1;29(1):44-70. doi: 10.1093/annonc/mdx738.

PMID:
29155929
20.

Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells.

Napolitano S, Martini G, Martinelli E, Della Corte CM, Morgillo F, Belli V, Cardone C, Matrone N, Ciardiello F, Troiani T.

Oncotarget. 2017 Aug 2;8(47):82773-82783. doi: 10.18632/oncotarget.19797. eCollection 2017 Oct 10.

21.

Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells.

Morgillo F, Della Corte CM, Diana A, Mauro CD, Ciaramella V, Barra G, Belli V, Franzese E, Bianco R, Maiello E, de Vita F, Ciardiello F, Orditura M.

Oncotarget. 2017 Aug 22;8(44):76479-76491. doi: 10.18632/oncotarget.20385. eCollection 2017 Sep 29.

22.

Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice.

Laterza MM, Pompella L, Petrillo A, Tirino G, Pappalardo A, Orditura M, Troiani T, Ciardiello F, Di Martino N, De Vita F.

Med Oncol. 2017 Oct 17;34(11):186. doi: 10.1007/s12032-017-1046-7.

PMID:
29043514
23.

Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme.

Sforza V, Martinelli E, Cardone C, Martini G, Napolitano S, Vitiello PP, Vitale P, Zanaletti N, Reginelli A, Bisceglie MD, Latiano TP, Bochicchio AM, Cecere F, Selvaggi F, Ciardiello F, Troiani T.

ESMO Open. 2017 Sep 21;2(4):e000229. doi: 10.1136/esmoopen-2017-000229. eCollection 2017.

24.

Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer.

Belli V, Sforza V, Cardone C, Martinelli E, Barra G, Matrone N, Napolitano S, Morgillo F, Tuccillo C, Federico A, Dallio M, Loguercio C, Gravina AG, De Palma R, Ciardiello F, Troiani T.

Oncotarget. 2017 Aug 7;8(40):68305-68316. doi: 10.18632/oncotarget.20054. eCollection 2017 Sep 15.

25.

Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation.

Napolitano S, Martini G, Martinelli E, Belli V, Parascandolo A, Laukkanen MO, Sforza V, Morgillo F, Ciardiello D, Ciardiello F, Troiani T.

Oncotarget. 2017 Jun 27;8(40):67592-67604. doi: 10.18632/oncotarget.18749. eCollection 2017 Sep 15.

26.

RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.

Normanno N, Esposito Abate R, Lambiase M, Forgione L, Cardone C, Iannaccone A, Sacco A, Rachiglio AM, Martinelli E, Rizzi D, Pisconti S, Biglietto M, Bordonaro R, Troiani T, Latiano TP, Giuliani F, Leo S, Rinaldi A, Maiello E, Ciardiello F; CAPRI-GOIM Investigators.

Ann Oncol. 2018 Jan 1;29(1):112-118. doi: 10.1093/annonc/mdx417.

PMID:
28950295
27.

Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients.

Kim L, Saieg M, Di Maio M, Gallo C, Butts C, Ciardiello F, Feld R, Cheng D, Gebbia V, Burgio MA, Alam Y, Signoriello S, Rossi A, Leighl N, Maione P, Morabito A, Liu G, Tsao MS, Perrone F, Gridelli C.

Oncotarget. 2017 Feb 25;8(34):57528-57536. doi: 10.18632/oncotarget.15725. eCollection 2017 Aug 22.

28.

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.

Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, Rauh S, Zielinski CC, Stahel RA, Voest E, Douillard JY, McGregor K, Ciardiello F.

ESMO Open. 2017 Jan 16;1(6):e000142. doi: 10.1136/esmoopen-2016-000142. eCollection 2016. Review.

29.

Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial.

Martinelli E, Cardone C, Troiani T, Normanno N, Pisconti S, Sforza V, Bordonaro AR, Rachiglio AM, Lambiase M, Latiano TP, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E, Ciardiello F.

ESMO Open. 2017 Feb 20;1(6):e000086. doi: 10.1136/esmoopen-2016-000086. eCollection 2016.

30.

Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer.

Morgillo F, Amendola G, Della Corte CM, Giacomelli C, Botta L, Di Maro S, Messere A, Ciaramella V, Taliani S, Marinelli L, Trincavelli ML, Martini C, Novellino E, Ciardiello F, Cosconati S.

J Med Chem. 2017 Sep 14;60(17):7447-7458. doi: 10.1021/acs.jmedchem.7b00794. Epub 2017 Aug 22.

PMID:
28787156
31.

Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.

Martini G, Troiani T, Cardone C, Vitiello P, Sforza V, Ciardiello D, Napolitano S, Della Corte CM, Morgillo F, Raucci A, Cuomo A, Selvaggi F, Ciardiello F, Martinelli E.

World J Gastroenterol. 2017 Jul 14;23(26):4675-4688. doi: 10.3748/wjg.v23.i26.4675. Review.

32.

Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial).

Orditura M, Gravina A, Riccardi F, Diana A, Mocerino C, Leopaldi L, Fabozzi A, Giordano G, Nettuno R, Incoronato P, Barzelloni ML, Caputo R, Pisano A, Grimaldi G, Genua G, Montesarchio V, Barbato E, Iodice G, Lieto E, Procaccini E, Mabilia R, Febbraro A, Laurentiis M, Ciardiello F.

ESMO Open. 2017 Jun 2;2(2):e000176. doi: 10.1136/esmoopen-2017-000176. eCollection 2017.

33.

Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer.

Morgillo F, Fasano M, Della Corte CM, Sasso FC, Papaccio F, Viscardi G, Esposito G, Di Liello R, Normanno N, Capuano A, Berrino L, Vicidomini G, Fiorelli A, Santini M, Ciardiello F.

ESMO Open. 2017 May 2;2(2):e000132. doi: 10.1136/esmoopen-2016-000132. eCollection 2017.

34.

Implication of the Hedgehog pathway in hepatocellular carcinoma.

Della Corte CM, Viscardi G, Papaccio F, Esposito G, Martini G, Ciardiello D, Martinelli E, Ciardiello F, Morgillo F.

World J Gastroenterol. 2017 Jun 28;23(24):4330-4340. doi: 10.3748/wjg.v23.i24.4330. Review.

35.

Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.

Della Corte CM, Malapelle U, Vigliar E, Pepe F, Troncone G, Ciaramella V, Troiani T, Martinelli E, Belli V, Ciardiello F, Morgillo F.

Oncotarget. 2017 Apr 4;8(14):23020-23032. doi: 10.18632/oncotarget.15479.

36.

Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.

Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP, Tabernero J, Cervantes A, Ciardiello F.

Ann Oncol. 2017 Aug 1;28(8):1713-1729. doi: 10.1093/annonc/mdx175.

PMID:
28407110
37.

EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients.

Srivatsa S, Paul MC, Cardone C, Holcmann M, Amberg N, Pathria P, Diamanti MA, Linder M, Timelthaler G, Dienes HP, Kenner L, Wrba F, Prager GW, Rose-John S, Eferl R, Liguori G, Botti G, Martinelli E, Greten FR, Ciardiello F, Sibilia M.

Gastroenterology. 2017 Jul;153(1):178-190.e10. doi: 10.1053/j.gastro.2017.03.053. Epub 2017 Apr 9.

38.

Complete response to capecitabine in a frail, elderly patient with metastatic colorectal cancer: A case report.

Fasano M, Fabozzi A, Giordano G, Venturini F, Aurilio G, Cantile F, Fabozzi T, Ricci V, Santabarbara G, Morgillo F, Ciardiello F, De Vita F.

Oncol Lett. 2017 Feb;13(2):979-983. doi: 10.3892/ol.2016.5523. Epub 2016 Dec 20.

39.

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).

Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M.

ESMO Open. 2016 Dec 7;1(6):e000107. doi: 10.1136/esmoopen-2016-000107. eCollection 2016. Review.

40.

Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review.

Fasano M, Della Corte CM, Vicidomini G, Scotti V, Rambaldi PF, Fiorelli A, Accardo M, De Vita F, Santini M, Ciardiello F, Morgillo F.

Oncol Lett. 2016 Dec;12(6):4505-4509. doi: 10.3892/ol.2016.5279. Epub 2016 Oct 18.

41.

Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.

Martinelli E, Morgillo F, Troiani T, Ciardiello F.

Cancer Treat Rev. 2017 Feb;53:61-69. doi: 10.1016/j.ctrv.2016.12.001. Epub 2016 Dec 30. Review.

PMID:
28073102
42.

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.

Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF; EMPHASIS-lung Collaborative Group.

J Thorac Oncol. 2017 Apr;12(4):752-762. doi: 10.1016/j.jtho.2016.12.017. Epub 2016 Dec 23.

43.

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR; OAK Study Group.

Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.

PMID:
27979383
44.

Quality to rely on: meeting report of the 5th Meeting of External Quality Assessment, Naples 2016.

van Krieken H, Deans S, Hall JA, Normanno N, Ciardiello F, Douillard JY.

ESMO Open. 2016 Nov 18;1(5):e000114. eCollection 2016. No abstract available.

45.

Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required?

Federico A, Brancaccio G, Dallio M, Iodice P, Fabozzi A, Del Prete S, Ciardiello F, Loguercio C, Gaeta GB.

Dig Liver Dis. 2017 Feb;49(2):197-201. doi: 10.1016/j.dld.2016.11.004. Epub 2016 Nov 16.

PMID:
27899262
46.

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence.

Troiani T, Napolitano S, Della Corte CM, Martini G, Martinelli E, Morgillo F, Ciardiello F.

ESMO Open. 2016 Sep 16;1(5):e000088. eCollection 2016. Review.

47.

Mechanisms of resistance to EGFR-targeted drugs: lung cancer.

Morgillo F, Della Corte CM, Fasano M, Ciardiello F.

ESMO Open. 2016 May 11;1(3):e000060. eCollection 2016. Review.

48.

ESMO and WHO: 14 years of working in partnership on cancer control.

Ullrich A, Ciardiello F, Bricalli G, Cherny NI, Eniu A.

ESMO Open. 2016 May 26;1(3):e000012. eCollection 2016. No abstract available.

49.

Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis.

Orditura M, Galizia G, Diana A, Saccone C, Cobellis L, Ventriglia J, Iovino F, Romano C, Morgillo F, Mosca L, Diadema MR, Lieto E, Procaccini E, De Vita F, Ciardiello F.

ESMO Open. 2016 Mar 7;1(2):e000038. eCollection 2016.

50.

The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy.

Perrone F, Jommi C, Di Maio M, Gimigliano A, Gridelli C, Pignata S, Ciardiello F, Nuzzo F, de Matteis A, Del Mastro L, Bryce J, Daniele G, Morabito A, Piccirillo MC, Rocco G, Guizzaro L, Gallo C.

Ann Oncol. 2016 Dec;27(12):2224-2229. doi: 10.1093/annonc/mdw433. Epub 2016 Oct 26.

PMID:
27789469

Supplemental Content

Loading ...
Support Center